| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.933 | 0.001 | 0.933 | Ornithine decarboxylase inhibitor | 0.88 0.001 DBMET01005 | ||
| 0.774 | 0.001 | 0.812 | Keratolytic | 0.812 0.001 DBMET01005 | DBMET01005 | |
| 0.652 | 0.001 | 0.735 | Retinoic acid receptor agonist | 0.735 0.001 DBMET01005 | DBMET01005 | |
| 0.585 | 0.001 | 0.678 | Retinoic acid alpha receptor agonist | 0.678 0.001 DBMET01005 | DBMET01005 | |
| 0.548 | 0.001 | 0.684 | Retinoic acid beta receptor agonist | 0.684 0.001 DBMET01005 | DBMET01005 | |
| 0.5 | 0.004 | 0.521 | Glutamate (mGluR) antagonist | 0.521 0.004 DBMET01005 | DBMET01005 | |
| 0.496 | 0.003 | 0.51 | Glutamate (mGluR group I) antagonist | 0.51 0.003 DBMET01005 | DBMET01005 | |
| 0.473 | 0.005 | 0.543 | Glutamate receptor antagonist | 0.543 0.004 DBMET01005 | DBMET01005 | |
| 0.468 | 0.001 | 0.549 | Retinoic acid gamma receptor agonist | 0.549 0.001 DBMET01005 | DBMET01005 | |
| 0.459 | 0.003 | 0.48 | Glutamate (mGluR5) antagonist | 0.48 0.003 DBMET01005 | DBMET01005 | |
| 0.4 | 0.004 | 0.49 | Glutamate (mGluR) agonist | 0.49 0.004 DBMET01005 | DBMET01005 | |
| 0.285 | 0.002 | 0.573 | Retinoic acid alpha receptor antagonist | 0.573 0.001 DBMET01005 | DBMET01005 | |
| 0.264 | 0.005 | 0.333 | ABCA1 expression enhancer | 0.333 0.005 DBMET01005 | DBMET01005 | |
| 0.248 | 0.002 | 0.568 | Retinoic acid receptor antagonist | 0.568 0.001 DBMET01005 | DBMET01005 | |
| 0.345 | 0.111 | 0.422 | Analgesic | 0.422 0.075 DBMET01005 | DBMET01005 | |
| 0.357 | 0.135 | 0.389 | Apoptosis agonist | 0.389 0.119 DBMET01005 | DBMET01005 | |
| 0.294 | 0.098 | 0.294 | Calcium channel activator | |||
| 0.288 | 0.098 | 0.288 | Vasodilator, coronary | |||
| 0.276 | 0.107 | 0.276 | Cholesterol antagonist | 0.254 0.122 DBMET01005 | ||
| 0.17 | 0.002 | 0.449 | Retinoic acid receptor gamma antagonist | 0.449 0.001 DBMET01005 | DBMET01005 | |
| 0.167 | 0.002 | 0.424 | Retinoic acid beta receptor antagonist | 0.424 0.001 DBMET01005 | DBMET01005 | |
| 0.16 | 0.009 | 0.16 | Calcium channel L-type blocker | 0.075 0.045 DBMET01005 | ||
| 0.184 | 0.048 | 0.198 | Catenin beta inhibitor | 0.198 0.034 DBMET01005 | DBMET01005 | |
| 0.299 | 0.166 | 0.395 | 5 Hydroxytryptamine release inhibitor | 0.395 0.081 DBMET01005 | DBMET01005 | |
| 0.132 | 0.003 | 0.16 | Retinoid X gamma receptor agonist | 0.16 0.002 DBMET01005 | DBMET01005 | |
| 0.292 | 0.164 | 0.292 | Calcium channel L-type activator | |||
| 0.201 | 0.082 | 0.201 | Anticonvulsant | 0.143 0.138 DBMET01005 | ||
| 0.114 | 0.003 | 0.204 | Retinoid X beta receptor agonist | 0.204 0.002 DBMET01005 | DBMET01005 | |
| 0.108 | 0.005 | 0.199 | Retinoid X alpha receptor agonist | 0.199 0.002 DBMET01005 | DBMET01005 | |
| 0.105 | 0.004 | 0.146 | Retinoid X receptor agonist | 0.146 0.003 DBMET01005 | DBMET01005 | |
| 0.154 | 0.055 | 0.154 | Calcium channel blocker | |||
| 0.139 | 0.048 | 0.144 | Interleukin 1b antagonist | 0.144 0.045 DBMET01005 | DBMET01005 | |
| 0.101 | 0.013 | 0.101 | Transcription factor AP-1 inhibitor | |||
| 0.167 | 0.08 | 0.167 | Tumour necrosis factor antagonist | |||
| 0.196 | 0.116 | 0.202 | Hypoglycemic | 0.202 0.11 DBMET01005 | DBMET01005 | |
| 0.161 | 0.085 | 0.161 | 3C-like protease (Human coronavirus) inhibitor | 0.149 0.103 DBMET01005 | ||
| 0.156 | 0.091 | 0.195 | Dual specificity phosphatase 3 inhibitor | 0.195 0.064 DBMET01005 | DBMET01005 | |
| 0.183 | 0.119 | 0.183 | Vasodilator | |||
| 0.08 | 0.018 | 0.08 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.097 | 0.039 | 0.275 | Glutamate receptor agonist | 0.275 0.005 DBMET01005 | DBMET01005 | |
| 0.094 | 0.046 | 0.094 | Transcription factor NF kappa B stimulant | 0.087 0.055 DBMET01005 | ||
| 0.125 | 0.082 | 0.125 | Interleukin 1 antagonist | 0.109 0.106 DBMET01005 | ||
| 0.064 | 0.021 | 0.08 | Leukotriene C antagonist | 0.08 0.008 DBMET01005 | DBMET01005 | |
| 0.039 | 0.005 | 0.047 | Retinoid X gamma receptor antagonist | 0.047 0.003 DBMET01005 | DBMET01005 | |
| 0.157 | 0.13 | 0.178 | Hypolipemic | 0.178 0.111 DBMET01005 | DBMET01005 | |
| 0.161 | 0.135 | 0.161 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.164 | 0.14 | 0.164 | Tumour necrosis factor alpha release inhibitor | |||
| 0.2 | 0.176 | 0.2 | Vasodilator, peripheral | |||
| 0.211 | 0.189 | 0.256 | Histamine release inhibitor | 0.256 0.151 DBMET01005 | DBMET01005 | |
| 0.046 | 0.024 | 0.046 | GABA B receptor antagonist | |||
| 0.268 | 0.248 | 0.391 | Antiinflammatory | 0.391 0.145 DBMET01005 | DBMET01005 | |
| 0.041 | 0.022 | 0.056 | Leukotriene C4 antagonist | 0.056 0.007 DBMET01005 | DBMET01005 | |
| 0.078 | 0.066 | 0.078 | Calcium antagonist | |||
| 0.046 | 0.035 | 0.082 | Glutamate (mGluR group I) agonist | 0.082 0.012 DBMET01005 | DBMET01005 | |
| 0.097 | 0.089 | 0.097 | Calcium channel (voltage-sensitive) blocker | |||
| 0.092 | 0.087 | 0.092 | GABA receptor agonist | |||
| 0.028 | 0.024 | 0.05 | Somatostatin 5 antagonist | 0.05 0.013 DBMET01005 | DBMET01005 | |
| 0.059 | 0.057 | 0.076 | Leukotriene synthesis inhibitor | 0.076 0.04 DBMET01005 | DBMET01005 | |
| 0.119 | 0.118 | 0.128 | NOS3 expression enhancer | 0.128 0.101 DBMET01005 | DBMET01005 | |
| 0.043 | 0.043 | 0.045 | Baculoviral IAP repeat-containing protein inhibitor | 0.045 0.036 DBMET01005 | DBMET01005 | |
| 0.013 | 0.019 | 0.019 | Free fatty acid receptor 1 agonist | 0.019 0.011 DBMET01005 | DBMET01005 | |
| 0.039 | 0.045 | 0.063 | Glutamate (mGluR5) agonist | 0.063 0.016 DBMET01005 | DBMET01005 | |
| 0.03 | 0.037 | 0.045 | Farnesoid X receptor agonist | 0.045 0.018 DBMET01005 | DBMET01005 | |
| 0.123 | 0.132 | 0.16 | Dual specificity phosphatase inhibitor | 0.16 0.084 DBMET01005 | DBMET01005 | |
| 0.029 | 0.038 | 0.048 | Retinoid X alpha receptor antagonist | 0.048 0.008 DBMET01005 | DBMET01005 | |
| 0.031 | 0.043 | 0.055 | Retinoid X receptor antagonist | 0.055 0.009 DBMET01005 | DBMET01005 | |
| 0.094 | 0.107 | 0.13 | Cyclooxygenase 1 inhibitor | 0.13 0.071 DBMET01005 | DBMET01005 | |
| 0.046 | 0.063 | 0.07 | DNA helicase inhibitor | 0.07 0.017 DBMET01005 | DBMET01005 | |
| 0.112 | 0.131 | 0.127 | MAP3K9 inhibitor | 0.127 0.1 DBMET01005 | DBMET01005 | |
| 0.024 | 0.049 | 0.054 | Nicotinic acid receptor 2 agonist | 0.054 0.013 DBMET01005 | DBMET01005 | |
| 0.015 | 0.049 | 0.024 | Retinoid X beta receptor antagonist | 0.024 0.008 DBMET01005 | DBMET01005 | |
| 0.044 | 0.09 | 0.067 | DNA gyrase inhibitor | 0.067 0.04 DBMET01005 | DBMET01005 | |
| 0.017 | 0.067 | 0.054 | Nicotinic acid receptor agonist | 0.054 0.013 DBMET01005 | DBMET01005 | |
| 0.041 | 0.094 | 0.064 | Leukotriene antagonist | 0.064 0.046 DBMET01005 | DBMET01005 | |
| 0.108 | 0.201 | 0.135 | CC chemokine 6 receptor antagonist | 0.135 0.054 DBMET01005 | DBMET01005 | |
| 0.216 | 0.349 | 0.358 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.358 0.142 DBMET01005 | DBMET01005 | |
| 0.068 | 0.216 | 0.12 | Protein-tyrosine phosphatase inhibitor | 0.12 0.114 DBMET01005 | DBMET01005 | |
| 0.037 | 0.189 | 0.056 | Ryanodine receptor antagonist | 0.056 0.051 DBMET01005 | DBMET01005 | |
| 0.168 | 0.327 | 0.288 | Cyclophilin D inhibitor | 0.288 0.174 DBMET01005 | DBMET01005 | |
| 0.031 | 0.233 | 0.084 | Alcohol dehydrogenase inhibitor | 0.084 0.073 DBMET01005 | DBMET01005 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |